

Olmesartan Formulation

2.4	Revision Date: 10.10.2020		S Number: '973-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016
SECTION	1. PRODUCT AND CO	OMPA	NY IDENTIFICA	TION
Produ	uct name	:	Olmesartan Fo	rmulation
Manu	facturer or supplier's	detai	ls	
Comp	bany	:	Organon & Co.	
Addre	ess	:	Rua Treze de N Campinas, São	/aio, 1161 Paulo, Brazil B-2220
Telep	hone	:	551-430-6000	
Emer	gency telephone	:	215-631-6999	
E-ma	il address	:	EHSSTEWARD	@organon.com
Reco	mmended use of the	chem	ical and restrict	ions on use
Reco	mmended use	:	Pharmaceutica	l
Ponro				
Керк	oductive toxicity	:	Category 1A	
	oductive toxicity		0,	IBR 14725 Standard
GHS			0,	IBR 14725 Standard
GHS Haza	label elements in acc		0,	IBR 14725 Standard
GHS Haza Signa	label elements in acc rd pictograms		Danger	IBR 14725 Standard mage the unborn child.
GHS Haza Signa Haza	label elements in acc rd pictograms Il Word		Danger H360D May da Prevention: P201 Obtain sp	mage the unborn child. recial instructions before use. tective gloves/ protective clothing/ eye prot
GHS Haza Signa Haza	label elements in accord rd pictograms al Word rd Statements		Danger H360D May da Prevention: P201 Obtain sp P280 Wear pro tion/ face protect	mage the unborn child. recial instructions before use. tective gloves/ protective clothing/ eye prot
GHS Haza Signa Haza	label elements in accord rd pictograms al Word rd Statements		Danger H360D May da Prevention: P201 Obtain sp P280 Wear pro tion/ face protect Response: P308 + P313 IF	mage the unborn child. pecial instructions before use. tective gloves/ protective clothing/ eye pro ction.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	10.10.2020	717973-00011	Date of first issue: 01.06.2016

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Olmesartan	144689-63-4	Acute toxicity (Oral), Category 4 Eye irritation, Category 2B Reproductive toxicity, Category 1A	>= 5 -< 10
Cellulose	9004-34-6		>= 5 -< 10

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	May damage the unborn child. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire	:	Avoid generating dust; fine dust dispersed in air in sufficient



Version 2.4	Revision Date: 10.10.2020		9S Number: 7973-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016
fighti	ng		potential dust ex	and in the presence of an ignition source is a plosion hazard. nbustion products may be a hazard to health.
Haza ucts	ardous combustion prod-	:	Carbon oxides	
Spec ods	Specific extinguishing meth- ods		cumstances and Use water spray	ng measures that are appropriate to local cir- d the surrounding environment. v to cool unopened containers. aged containers from fire area if it is safe to do
	ial protective equipment re-fighters	:		re, wear self-contained breathing apparatus. otective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	 Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	 Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes.



Olmesartan Formulation

Version 2.4	Revision Date: 10.10.2020	SDS Number: 717973-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016			
Hygiene measures		 Handle in accordance with good industrial hygiene and safe practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to environment. If exposure to chemical is likely during typical use, provide flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. 				
Cone	ditions for safe storage	engineering co appropriate de industrial hygi use of adminis : Keep in prope Store locked u	•			
Mate	erials to avoid	 Keep tightly closed. Store in accordance with the particular national regulations. Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases 				

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

U				
Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Olmesartan	144689-63-4	TWA	30 µg/m3 (OEB 3)	Internal
		Wipe limit	300 µg/100 cm ²	Internal
Cellulose	9004-34-6	TWA	10 mg/m³	ACGIH

Ingredients with workplace control parameters

containment devices). Minimize open handling.	Engineering measures	
--	----------------------	--

Personal protective equipment

Respiratory protection	:	If adequate loca
		avpouro ocoo

If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.



Olmesartan Formulation

Version 2.4	Revision Date: 10.10.2020		lumber: 3-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016
	ter type protection	: Pa	rticulates type	
Ma	aterial	: Ch	emical-resistar	nt gloves
Remarks Eye protection		: We lf t mi: We po	he work enviro sts or aerosols ear a faceshield	gloving. ses with side shields or goggles. nment or activity involves dusty conditions, , wear the appropriate goggles. d or other full face protection if there is a t contact to the face with dusts, mists, or
Skin and body protection		Ad tas dis Us	ditional body g sk being perforr sposable suits)	aboratory coat. arments should be used based upon the med (e.g., sleevelets, apron, gauntlets, to avoid exposed skin surfaces. degowning techniques to remove potentially thing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available



Olmesartan Formulation

Version 2.4	Revision Date: 10.10.2020	SDS Number: 717973-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016
Relative density		: No data avai	lable
Dens	sity	: No data avai	lable
	oility(ies) /ater solubility	: No data avai	lable
	tion coefficient: n- nol/water	: No data avai	lable
	ignition temperature	: No data avai	lable
Decc	mposition temperature	: No data avai	lable
Visco Vi	osity iscosity, kinematic	: No data avai	lable
Explo	osive properties	: Not explosive	9
Oxidi	izing properties	: The substan	ce or mixture is not classified as oxidizing.
Mole	cular weight	: No data avai	lable
Parti	cle size	: No data avai	lable

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	Not classified as a reactivity haz Stable under normal conditions. May form explosive dust-air mix nandling or other means. Can react with strong oxidizing a	ture during processing,
Conditions to avoid	leat, flames and sparks. Avoid dust formation.	
Incompatible materials	Dxidizing agents	
Hazardous decomposition products	lo hazardous decomposition p	oducts are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact
exposure		Ingestion
		Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5.000 mg/kg
		Method: Calculation method



Olmesartan Formulation

	Revision Date: 10.10.2020	SDS Number: 717973-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016
<u>Com</u>	oonents:		
Olme	sartan:		
	oral toxicity	: LD50 (Rat):	> 2.000 mg/kg
		LD50 (Mous	e): > 2.000 mg/kg
		LD50 (Dog)	: > 1.500 mg/kg
Acute	inhalation toxicity	: Remarks: N	o data available
Acute	e dermal toxicity	: Remarks: N	o data available
Cellu	lose:		
Acute	oral toxicity	: LD50 (Rat):	> 5.000 mg/kg
Acute	inhalation toxicity	: LC50 (Rat): Exposure tir Test atmosp	
Acute	e dermal toxicity	: LD50 (Rabb	it): > 2.000 mg/kg
<u>Com</u>	oonents:		
-	sartan:	: No data ava	ilable
Olme Rema	sartan:		ilable
Olme Rema Serio	sartan: arks	irritation	ilable
Olme Rema Serio Not cl	esartan: arks ous eye damage/eye	irritation	ilable
Olme Rema Serio Not cl <u>Com</u>	e sartan: arks us eye damage/eye lassified based on ava	irritation	ilable
Olme Rema Serio Not cl Comp Olme Speci	esartan: arks us eye damage/eye lassified based on ava <u>conents:</u> esartan: es	irritation ailable information. : Rabbit	
Olme Rema Serio Not cl <u>Comp</u> Olme	esartan: arks us eye damage/eye lassified based on ava <u>ponents:</u> sartan: les lt	irritation ailable information.	
Olme Rema Serio Not cl Comp Olme Speci Resul Metho	esartan: arks us eye damage/eye lassified based on ava <u>ponents:</u> sartan: les lt	irritation ailable information. : Rabbit : Moderate ey : Draize Test	
Olme Rema Serio Not cl Comp Olme Speci Resul Metho Resp	esartan: arks us eye damage/eye lassified based on ava <u>ponents:</u> esartan: les lt od	irritation ailable information. : Rabbit : Moderate ey : Draize Test	
Olme Rema Serio Not cl Comp Olme Speci Resul Metho Resp Skin	esartan: arks us eye damage/eye lassified based on ava <u>ponents:</u> esartan: les lt od iratory or skin sensi	irritation ailable information. : Rabbit : Moderate ey : Draize Test tization	
Olme Rema Serio Not cl Comp Olme Speci Resul Metho Resp Skin Not cl Resp	esartan: arks us eye damage/eye lassified based on ava <u>conents:</u> es artan: les lt od iratory or skin sensi sensitization	irritation ailable information. : Rabbit : Moderate ey : Draize Test tization ailable information.	
Olme Rema Serio Not cl Comp Olme Speci Resul Metho Resp Skin Not cl Resp Not cl	esartan: arks us eye damage/eye lassified based on ava <u>conents:</u> esartan: les lt od iratory or skin sensi sensitization lassified based on ava iratory sensitization	irritation ailable information. : Rabbit : Moderate ey : Draize Test tization ailable information.	
Olme Rema Serio Not cl Comp Olme Speci Resul Metho Resp Skin Not cl Resp Not cl Resp	esartan: arks us eye damage/eye lassified based on ava <u>conents:</u> es artan: les it od iratory or skin sensi sensitization lassified based on ava iratory sensitization lassified based on ava	irritation ailable information. : Rabbit : Moderate ey : Draize Test tization ailable information.	



Olmesartan Formulation

rsion 1	Revision Date: 10.10.2020	SDS Number: 717973-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016
	cell mutagenicity assified based on ava	ilable information.	
<u>Comp</u>	oonents:		
	sartan: oxicity in vitro	: Test Type: E Result: nega	acterial reverse mutation assay (AMES) tive
		Test Type: N Result: nega	Iutagenicity (in vitro mammalian cytogenetic tes tive
			Chromosome aberration test in vitro Chinese hamster lung cells ive
		Test Type: N Result: nega	louse Lymphoma tive
Genot	oxicity in vivo	: Test Type: M Species: Mo Cell type: Bo Application I Result: nega	one marrow Route: Oral
	cell mutagenicity - sment	: Weight of ev cell mutager	idence does not support classification as a gern
Cellul	ose:		
Genot	oxicity in vitro	: Test Type: E Result: nega	acterial reverse mutation assay (AMES) tive
		Test Type: I Result: nega	n vitro mammalian cell gene mutation test tive
Genot	oxicity in vivo	cytogenetic Species: Mo	use Route: Ingestion

Components:

Olmesartan:

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative
Species Application Route	:	Mouse Oral



Vers 2.4	sion	Revision Date: 10.10.2020		DS Number: 7973-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016
	Exposu Result	ire time	:	6 Months negative	
			:	Rat Ingestion 72 weeks negative	
	-	ductive toxicity			
	Compo	onents:			
	Olmes	artan:			
	Effects	on fertility	:	Test Type: Fertility Species: Rat Application Route Fertility: NOAEL: Result: No effects	: Oral 1.000 mg/kg body weight
	Effects	on fetal development	:	Test Type: Develo Species: Rat Application Route Dose: 1000 milligu Result: No teratog	: Oral am per kilogram
				Test Type: Develo Species: Rabbit Application Route Dose: 1 milligram Result: No teratog	: Oral per kilogram
				Symptoms: Malfor weight	
	Reprod sessme	luctive toxicity - As- ent	:	Positive evidence human epidemiolo	of adverse effects on development from ogical studies.
	Cellulo	ose:			
		on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion
	Effects	on fetal development	:	Test Type: Fertilit Species: Rat Application Route	y/early embryonic development





Version 2.4	Revision Date: 10.10.2020		DS Number: 7973-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016
			Result: negative	
	OT-single exposure classified based on avail	lable	information.	
	OT-repeated exposure classified based on avail	lable	information.	
Rej	peated dose toxicity			
Co	mponents:			
Spe NO App Exp	nesartan: ecies AEL blication Route bosure time marks	:	2.000 mg/kg Oral 24 Months	verse effects were reported
Spe NO App	llulose: ecies AEL plication Route posure time		Rat >= 9.000 mg/kg Ingestion 90 Days	
Not	piration toxicity classified based on avail perience with human ex			
-	mponents:			
Olr Eye	nesartan: e contact estion	:	Symptoms: Eye in Symptoms: hypot Remarks: May ca Based on Human	tension ause harm to the unborn child.
SECTIO	N 12. ECOLOGICAL INF	ORI	MATION	
Eco	otoxicity			
Co	mponents:			
	l lulose: kicity to fish	:	Exposure time: 4	tipes (Japanese medaka)): > 100 mg/l 8 h on data from similar materials
Per	sistence and degradab	ility		

Components:

Cellulose:



/ersion 2.4	Revision Date: 10.10.2020	SDS Number: 717973-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016		
Biodegradability		: Result: Readi	ly biodegradable.		
	ccumulative potential ata available				
	lity in soil ata available				
	r adverse effects ata available				
CTION	13. DISPOSAL CONS	IDERATIONS			
Dispo	osal methods				
	e from residues aminated packaging	 Dispose of in accordance with local regulations. Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. 			
ECTION	14. TRANSPORT INF	ORMATION			
Interr	national Regulations				
UNR Not re	FDG egulated as a dangerou	is good			
IATA Not re	-DGR egulated as a dangerou	is good			
-	-Code egulated as a dangerou	is good			
	sport in bulk accordin pplicable for product as		ARPOL 73/78 and the IBC Code		
	estic regulation				
ANTT Not re	r egulated as a dangerou	is good			
ECTION	15. REGULATORY IN	FORMATION			
Safet mixtu		mental regulations	/legislation specific for the substance or		
Natio (LINA	nal List of Carcinogenic CH)	c Agents for Humans	s - : Not applicable		
Brazil Police	l. List of chemicals cont e	rolled by the Federa	al : Not applicable		
Interr	national Regulations				

International Regulations

The ingredients of this product are reported in the following inventories: AICS : not determined



Version Revision Date: 2.4 10.10.2020	SDS Number: 717973-00011	Date of last issue: 23.03.2020 Date of first issue: 01.06.2016
DSL	: not determined	
IECSC	: not determined	

SECTION 16. OTHER INFORMATION

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety Data Sheet	eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Dala Sheel	cy, mp.//echa.europa.eu/

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the





Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	10.10.2020	717973-00011	Date of first issue: 01.06.2016

SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8